Tuesday, 25 Feb 2020

You are here

Not All Hyperuricemia Leads to Gout

Dalbeth and colleagues studied 4 large prospective cohorts and found that rising levels of serum uric acid (SUA) leads to a non-linear increased risk of incident gout, but only half of those with SUA ≥10mg/dL developed clinically evident gout. 

Researchers analyzed four prospective cohorts (Atherosclerosis Risk in Communities Study, Coronary Artery Risk Development in Young Adults Study, and both the Original and Offspring cohorts of the Framingham Heart Study)  to assess the correlation between baseline SUA and the risk of incident gout.

There were 18 889 gout-free participants followed for a mean 11.2  years of follow-up.

The cumulative 15 year incidence of new gout cases varied according to baseline SUA:

  • SUA 6 mg/dL = 1.1% (0.9 to 1.4) 
  • SUA ≥10 mg/dL = 49% (31 to 67)

The adjusted hazard ration for incident gout was:

  • SUA 6.0-6.9 mg/dL - HR 2.7
  • SUA 7.0-7.9 mg/dL  - HR  6.6
  • SUA 8.0-8.9 mg/dL  - HR 15
  • SUA  9.0-9.9 mg/dL - HR 30
  • SUA ≥10 mg/dL - HR  64.

While hyperuricemia plays a significant role in causing gout, there are other factors, over time that along with prolonged hyperuricemia are necessary to lead to gout.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare: